Impact of electronic monitoring of drug adherence on blood pressure control in primary care: A cluster 12-month randomised controlled study

European Journal of Internal Medicine

Volumn 19, Issue 6, 2008, Pages 427-434

  Santschi, Valérie ^a   Rodondi, Nicolas ^a   Bugnon, Olivier ^a   Burnier, Michel ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b Department of Nephrology/Hypertension   (Switzerland)

Author keywords

Electronic monitoring device; Hypertension; Network of community pharmacists and general practitioners; Patient adherence

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; GENERAL PRACTITIONER; HUMAN; HYPERTENSION; INFORMATION SYSTEM; PATIENT COMPLIANCE; PATIENT MONITORING; PRIMARY MEDICAL CARE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; ELECTRONICS, MEDICAL; FEMALE; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 51449091027     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2007.12.007     Document Type: Article

References (37)

1. MacMahon S., Peto R., Cutler J., Collins R., Sorlie P., Neaton J., et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335 8692 (1990) 765-774
2. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., and He J. Global burden of hypertension: analysis of worldwide data. Lancet 365 (2005) 217-223
3. Neal B., MacMahon S., Chapman N., and Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood pressure lowering treatment trialists' collaboration. Lancet 356 (2000) 1955-1964
4. Ogden L.G., He J., Lydick E., and Whelton P.K. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 35 (2000) 539-543
5. Primatesta P., Brookes M., and Poulter N.R. Improved hypertension management and control: results from the health survey for England 1998. Hypertension 38 (2001) 827-832
6. Wolf-Maier K., Cooper R.S., Kramer H., Banegas J.R., Giampaoli S., Joffres M.R., et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 43 (2004) 10-17
7. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
8. McManus R.J., Mant J., Roalfe A., Oakes R.A., Bryan S., Pattison H.M., et al. Targets and self monitoring in hypertension: randomised controlled trial and cost effectiveness analysis. BMJ 331 (2005) 493
9. Phillips L.S., Branch W.T., Cook C.B., Doyle J.P., El-Kebbi I.M., Gallina D.L., et al. Clinical inertia. Ann Intern Med 135 (2001) 825-834
10. Jones J.K., Gorkin L., Lian J.F., Staffa J.A., and Fletcher A.P. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 311 (1995) 293-295
11. Ogden J., Ambrose L., Khadra A., Manthri S., Symons L., Vass A., et al. A questionnaire study of GPs' and patients' beliefs about the different components of patient centredness. Patient Educ Couns 47 (2002) 223-227
12. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 19 (2006) 1190-1196
13. Burnier M., Hess B., Greminger P., and Waeber B. Determinants of persistence in hypertensive patients treated with irbesartan: results of a postmarketing survey. BMC Cardiovasc Disord 5 (2005) 13. http://www.biomedcentral.com/1471-2261/5/13 Available at: www.biomedcentral.com/1471-2261/5/13
14. Wetzels G.E.C., Nelemans P., Schouten J.S., and Prins M.H. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 22 (2004) 1849-1855
15. Setaro J.F., and Black H.R. Refractory hypertension. N Engl J Med 327 (1992) 543-547
16. Yakovlevitch M., and Black H.R. Resistant hypertension in a tertiary care clinic. Arch Intern Med 151 (1991) 1786-1792
17. Burnier M., Schneider M.P., Chiolero A., Stubi C.L., and Brunner H.R. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 19 (2001) 335-341
18. Burnier M., Santschi V., Favrat B., and Brunner H.R. Monitoring compliance in resistant hypertension: an important step in patients management. J Hypertens 21 suppl2 (2003) s37-s42
19. Miller N.H., Hill M., Kottke T., and Ockene I.S. The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation 95 (1997) 1085-1090
20. Caro J.J., Speckman J.L., Salas M., Raggio G., and Jackson J.D. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. Can Med Assoc J 160 (1999) 41-46
21. Caro J.J., Salas M., Speckman J.L., Raggio G., and Jackson J.D. Persistence with treatment for hypertension in actual practice. Can Med Assoc J 160 (1999) 31-37
22. Bourgault C., Sénécal M., Brisson M., Marantette M.A., and Gregoire J.P. Persistence and disconinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens 8 (2005) 607-613
23. Cramer J.A., Mattson R.H., Prevey M.L., Scheyer R.D., and Ouellette V.L. How often is medication taken as prescribed? A novel assessment technique. JAMA 261 (1989) 3273-3277
24. Santschi V., Wuerzner G., Schneider M.P., Bugnon O., and Burnier M. Clinical evaluation of IDAS II, a new electronic device enabling drug adherence monitoring. Eur J Clin Pharmacol 63 (2007) 1179-1184
25. Urquhart J. The electronic medication event monitor - lessons for pharmacotherapy. Clin Pharmacokinet 32 (1997) 345-356
26. Bertholet N., Favrat B., Fallab-Stubi C.L., Brunner H.R., and Burnier M. Why objective monitoring of compliance is important for the management of hypertension. J Clin Hypertens 2 (2000) 258-262
27. Waeber B., Vetter W., Darioli R., Keller U., and Brunner H.R. Improved blood pressure control by monitoring compliance with antihypertensive therapy. Int J Clin Pract 53 (1999) 37-38
28. McKenney J.M., Munroe W.P., and Wright Jr. J.T. Impact of an electronic medication compliance aid on long-term blood pressure control. J Clin Pharmacol 32 (1992) 277-283
29. Wetzels G.E., Nelemans P.J., Schouten J.S., Dirksen C.D., van der Weijden T., Stoffers H.E., et al. Electronic monitoring of adherence as a tool to improve blood pressure control. A randomized controlled trial. Am J Hypertens 20 (2007) 119-125
30. Inkster M., Montgomery A., Donnan P., MacDonald T., Sullivan F., and Fahey T. Organisational factors in relation to control of blood pressure: an observational study. Br J Gen Pract 55 (2005) 931-937
31. Armitage P., Berry G., and Mathews J.N.S. Statistical methods in medical research. 4th ed. (2002), Blackwell, USA
32. DiMatteo M.R., Sherbourne C.D., Hays R.D., Ordway L., Kravitz R.L., McGlynn E.A., et al. Physicians characteristics influence patients adherence to medical treatment. Results from a medical outcomes study. Health Psychol 12 (1993) 93-102
33. Berlowitz D.R., Ash A.S., Hickey E.C., Friedman R.H., Glickman M., Kader B., et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 339 (1998) 1957-1963
34. Deary A.J., Schumann A.L., Murfet H., Haydock S.F., Foo R.S., and Brown M.J. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens 20 (2002) 771-777
35. Schroeder K., Fahey T., Hay A.D., Montgomery A., and Peters T.J. Relationship between medication adherence and blood pressure in primary care: prospective study. J Hum Hypertens 20 (2006) 625-627
36. Puffer S., Torgerson D., and Watson J. Evidence for risk of bias in cluster randomised trials: review of recent trials published in three general medical journals. BMJ 327 (2003) 785-789
37. Halpern M.T., Khan Z.M., Schmier J.K., Burnier M., Caro J.J., Cramer J., et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension 47 (2006) 1039-1048